TY  - JOUR 
AU  - Pombo Suárez, Manuel
AU  - Seoane-Mato, D.
AU  - Díaz-González, F.
AU  - Sánchez-Alonso, F.
AU  - Sánchez-Jareño, M.
AU  - Cea-Calvo, L.
AU  - Castrejón, I.
PY  - 2023
SN  - 2523-3106
UR  - http://hdl.handle.net/20.500.11940/21515
AB  - Background: In patients with rheumatic diseases, the use of biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) after discontinuation of tumor necrosis factor inhibitors (TNFi) is known to be effective. However,...
LA  - eng
KW  - Adult
KW  - Humans
KW  - Tumor Necrosis Factor Inhibitors
KW  - Arthritis, Psoriatic
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - Arthritis, Rheumatoid
KW  - Antirheumatic Agents
KW  - Rheumatic Fever
TI  - Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
DO  - 10.1186/s42358-023-00296-1
T2  - Advances in Rheumatology
KW  - AS Santiago
KW  - CHUS
VL  - 63
ER  -